Paltusotine Hydrochloride Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 20 mg, 30 mg

Reference Brands: Palsonify (USA)

Category: Immune Disorder

Paltusotine hydrochloride is available in Tablets and strengths such as 20 mg, 30 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Paltusotine hydrochloride is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Paltusotine hydrochloride can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Paltusotine hydrochloride, marketed under the brand name Palsonify, is an orally administered medication developed by Crinetics Pharmaceuticals for the treatment of acromegaly in adults. Acromegaly is a rare endocrine disorder caused by excessive secretion of growth hormone, most commonly due to a benign tumor of the pituitary gland. This hormonal imbalance leads to abnormal enlargement of bones, organs, and soft tissues, resulting in serious long-term health complications if left untreated.

Paltusotine hydrochloride acts as a selective somatostatin receptor type-2 agonist. By targeting this receptor, it helps suppress the excessive release of growth hormone and subsequently reduces insulin-like growth factor-1 levels in the body. Unlike traditional injectable therapies used in acromegaly management, paltusotine hydrochloride is administered orally, offering a more convenient treatment option for patients.

The medication is indicated for adults with acromegaly who have had an inadequate response to pituitary surgery or for whom surgical intervention is not a suitable option. Its oral formulation provides improved treatment flexibility and patient compliance while maintaining effective hormonal control. Paltusotine hydrochloride represents an important advancement in the management of acromegaly, addressing both therapeutic efficacy and patient quality of life.